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AbstrACt
Introduction Alcohol use disorder (AUD) is a major 
public health concern worldwide. In France, only 10% of 
people with AUD (PWAUD) receive medical care. General 
practitioners (GP) are one of the main entry points for AUD 
care. The present ongoing study, entitled ASIA (Access to 
Care and Indifference toward Alcohol, Accès aux Soins 
et Indifference à l’Alcool in French), aims to improve 
knowledge about factors associated with access to care 
for AUD by exploring related GP and PWAUD practices, 
experiences and perceptions.
Methods and analysis The ASIA project is an ongoing 
cross-sectional multisite study based on a complementary 
mixed-method approach (quantitative and qualitative) 
using a convergent parallel design. The double-perspective 
design of the study will enable us to collect and compare 
data regarding both PWAUD and GP points of view. For the 
PWAUD quantitative study, 260 PWAUD will be interviewed 
using a telephone-based questionnaire. For the qualitative 
study, 36 PWAUD have already been interviewed. The GP 
quantitative study will include 100 GP in a 15 min survey. 
Fifteen GP have already participated in semistructured 
interviews for the qualitative study. Logistic regression 
will be used to identify predictors for access to care. 
With respect to data analyses, qualitative interviews will 
be analysed using semantic analysis while quantitative 
logistic regression will be used for quantitative interviews.
Ethics and dissemination This study was approved by 
the CNIL (French National Commission on Informatics and 
Liberties) (approval reference number: C16-10, date of 
approval: 17 July 2017), the CCTIRS (Advisory Committee 
on Information Processing in Material Research in the Field 
of Health) and the CEEI (Evaluation and Ethics Committee) 
(approval reference number: 16–312, date of approval: 
8 July 2016) of INSERM (French National Institute of 
Health and Medical Research). Results from ASIA will be 
disseminated in peer-reviewed publications, conference 
presentations, reports and in a PhD thesis.
IntroduCtIon
Alcohol use disorder (AUD) is a major health 
and social concern and is responsible for 
approximately 3.3 million deaths (or 5.9% 
of all global deaths) annually.1 It is estimated 
that AUD contributes to over 200 diseases and 
injury conditions, especially liver cirrhosis and 
cancer.1 The prevalence of alcohol depen-
dence in Europe has been evaluated at 6.4% 
among men and 1.2% among women.2 Only 
10% of people concerned by AUD receive 
medical care for AUD in France.3 
According to a report on alcohol use, 
published by the French Observatory on 
Drugs and Drug Addiction (OFDT) in 
2014,4 5 10% of people interviewed in the 
country (n=15 635) reported daily alcohol 
consumption. A report published in 20156 
estimated the annual external cost of alcohol 
abuse at €114,399 billion, in terms of lost 
lives, reduced quality of life and production 
losses.
In France, it is difficult to obtain accurate 
figures on care for AUD due to the different 
AUD management entry points7 (specialised 
centres, general practitioners (GP), hospitals, 
strengths and limitations of this study
 ► The originality of this study is that it cross-analyses 
general  practitioner (GP) and people with alcohol 
use disorder (PWAUD) data regarding a common is-
sue. Its results will be very useful for improving AUD 
management in primary care and, consequently, for 
improving access to care for PWAUD in general.
 ► The major strength of this study is its mixed use of 
qualitative and quantitative data, which enables us 
to collect subjective data—such as perceptions—as 
well as data on measurable variables, both elements 
being involved in the patient’s AUD care trajectory.
 ► Another strength is the recruitment of both PWAUD 
involved and PWAUD not involved in AUD care, so 
that barriers as well as levers to access to care can 
be identified.
 ► The study population with AUD enrolled in the study 
may not be completely representative of the general 
population with AUD in France, and data may need 
appropriate weighting during analysis.
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associations), but the proportion of people with AUD 
(PWAUD) linked to medical care for this disorder is defi-
nitely small.8
Although medical care for substance use disorders is 
easily accessible in  Care, Prevention, and Support Centre 
for Addiction (CSAPA), GP constitute the main first line 
of care for AUD screening. Primary healthcare provided 
by GP is the first-choice option for preventing, screening 
and managing AUD and its consequences. Indeed, 
in addition to being the first point of contact, GP are 
numerous and provide comprehensive and coordinated 
care.9 10
Depending on the severity of the disorder, different 
psychosocial approaches can be used to help PWAUD 
reduce or stop alcohol, including motivational inter-
views, mindfulness interventions, social skills training and 
behavioural self-control training.11 In addition, five 
different pharmacological treatments can be prescribed: 
acamprosate, disulfiram, naltrexone, nalmefene and 
baclofen.12 Acamprosate and disulfiram are prescribed 
to help maintain abstinence in people who have already 
stopped drinking. Naltrexone is approved for abstinence 
maintenance, but has also been used off-label to reduce 
consumption.13 Nalmefene is prescribed to reduce 
consumption as it reduces craving. Baclofen is also used 
to reduce craving, but unlike the other four drugs, which 
are legally available in France, it can only be prescribed 
off-label, as part of France’s regulatory drug evaluation 
framework (called ‘Temporary Recommendation Use 
(TRU)’). A review published in 2016 concluded that all 
five treatments show different safety profiles and must be 
adapted to each patient’s alcohol consumption goal and 
individual profile.14 Another review reported that all five 
treatments are still underused and that barriers to their 
prescription need to be investigated.15
It is important to note that we are in a transitional 
period between one paradigm and another. More specifi-
cally, alcohol-related risk reduction, including controlled 
drinking (CD), is becoming an acceptable therapeutic 
goal for caregivers and patients16 ;until very recently, the 
standard of care for AUD was based on stopping consump-
tion, maintaining abstinence, preventing chronic compli-
cations related to excessive alcohol consumption and 
managing withdrawal symptoms. The licensing of nalme-
fene and the prescription of baclofen within France’s 
TRU framework confirm this paradigm shift.17 For many 
patients who might not be immediately ready for total 
abstinence, reducing consumption may constitute a real-
istic achievable goal.18
Lack of awareness of having AUD and apprehen-
sion towards total alcohol abstinence are two important 
barriers to treatment seeking.19 It is possible that a lack of 
knowledge about the different AUD therapeutic options 
currently available20 also constitutes a barrier.
Given this dynamic context, an in-depth evaluation of 
access to care for PWAUD in France would seem neces-
sary. The present study, Accès aux Soins et Indifference à 
l’Alcool (ASIA), aims to improve knowledge about factors 
associated with seeking, receiving and providing care for 
AUD by exploring related GP and PWAUD practices, 
experiences and perceptions.
General study design
ASIA is an ongoing multisite cross-sectional study which 
started in France in 2016. It aims to explore barriers to 
and facilitators of access to care for PWAUD in France, 
and to provide a better understanding of the individual 
and contextual factors associated with the currently 
poor level of access to care for those who wish to stop 
or reduce their alcohol consumption. The study uses a 
mixed approach which comprises (1) a qualitative study 
and (2) a quantitative study for two populations: PWAUD 
(1) and GP (2).
The complementary mixed-method approach (quanti-
tative and qualitative) implemented here uses a conver-
gent parallel design.21 This type of study design provides 
a more comprehensive view of a phenomenon, as it sepa-
rately cross-analyses data collected concomitantly using 
these two study approaches from each of two different 
studies (in our situation PWAUD and GP). For the present 
work, comparing data from the resulting four substudies 
will shed greater light on the mechanisms leading or not 
to AUD care.
MEthods And AnAlysIs
objectives
The specific objectives of the study are presented 
below. Relationship between project objectives and study 
components are resumed in table 1.
1. Identify sociodemographic characteristics and health 
experiences associated with access to care (PWAUD).
2. Determine sociodemographic and professional char-
acteristics associated with AUD management and 
screening, acceptance of CD and AUD pharmacolog-
ical treatment prescription (GP).
3. Assess whether barriers found in other studies were 
relevant in the current French context (PWAUD and 
GP).
4. Identify other barriers and levers which could have 
been missed in the quantitative study (GP and 
PWAUD).
5. Illustrate and examine in depth the findings of the 
quantitative study (GP and PWAUD).
definition of Aud
The main tool used by the WHO to measure alcohol 
consumption is the Alcohol Use Disorders Identification 
Test (AUDIT).22 This 10-item questionnaire provides an 
alcohol consumption score from 0 to 40. Scores between 
8 (7 for women) and 15 suggest hazardous alcohol 
consumption, 16 and 19 harmful alcohol consumption 
and >20 alcohol dependence.15 We chose to include only 
people with a score >15, because above this, medical care 
is recommended.11
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definition of care
In this study, we decided to define ‘receiving care’ as 
follows:
 ► Receiving non-pharmacological therapeutic interven-
tions from a healthcare professional to reduce or stop 
alcohol consumption
and/or
 ► Participating in an alcohol-related support group 
(such as Alcoholics Anonymous)
and/or:
 ► Taking one of the five approved AUD pharmacolog-
ical drugs
Patient and public involvement statement
Neither patients nor the general public were involved in 
the design of this study.
In order to respect patient confidentiality, we will not 
keep participants' contact information. Consequently, the 
results of the study will not be personally disseminated 
to participants. Participants are informed in the consent 
form that if they wish, they can contact the main investi-
gator to obtain the study results.
sampling strategy and data collection
As of May 2018, data collection for the qualitative 
substudies has already been performed for the PWAUD 
and GP. Analysis of qualitative GP data has also been 
completed. More in-depth details can be found in this 
section.
PWAUD population
Inclusion criteria
For both substudies (ie, quantitative and qualitative), 
the following inclusion criteria are used: aged over 18, 
French speaking and AUDIT score >15.
Qualitative substudy
Recruitment and data collection
From June 2016 to May 2017, 36 patients were recruited 
in four medical services: the Saint-Barnabe substance 
disorder clinic in Marseille, two CSAPA (Care, Preven-
tion, and Support Centre for Addiction) in Avignon and 
Nîmes and the CISIH (Information and Care Centre for 
Human Immunodeficiency) in Saint-Marguerite Hospital 
in Marseille (patients recruited through this service were 
not already receiving AUD care at enrolment). Medical 
staff informed their patients of the study and introduced 
potential participants to the study investigator.
After providing information about the study, the study 
investigator performed a face-to-face interview in a 
closed office to ensure confidentiality. The interview was 
semistructured and conducted according to the guide 
described in table 2.
Interviews lasted between 30 and 75 min and were 
recorded. Recordings were transcribed using word 
processing software. Transcripts of interviews were not 
returned to PWAUD participants for comments or correc-
tion. Only the qualitative substudy investigator has access 
to these records. Information concerning participants’ 
confidentiality and anonymity is presented in the Ethics 
and Dissemination section.
data analysis
The qualitative data for the PWAUD interview corpus 
has yet to be analysed (as of June 2018). The text anal-
ysis software Iramuteq (Interface de R pour les Analyses 
Multidimensionnelles de Textes et de Questionnaires) 
(V.0.7 Alpha 2) will be used. Iramuteq provides different 
processing and statistical analysis options for produced 
texts and ensures accurate analyses for qualitative health 
research.
Descending hierarchical classification will be 
performed, whereby calculations are performed on the 
concurrence of words in the text.23 The results come in 
the form of speech classes that are statistically over-rep-
resented in the segments gathered in the classes. Each of 
the lexical classes is described in detail by the lexicon that 
defines it, the characteristic segments that represent it, 
and the associated variables.24
Table 1 Relationship between project objectives and study components
PWAUD
qualitative 
study
PWAUD 
quantitative 
study
GP
qualitative 
study
GP
quantitative 
study
(1) Identify sociodemographic characteristics and health experiences 
associated with access to care (PWAUD).
X
(2) Determine sociodemographic and professional characteristics 
associated with AUD management and screening, acceptance of CD 
and pharmacological treatment prescription (GP).
X
(3) Assess whether barriers found in other studies were relevant in the 
current French context (PWAUD and GP).
X X
(4) Identify other barriers and levers which could have been missed in 
the quantitative study (GP and PWAUD).
X X
(5) Illustrate and examine in depth the findings of the quantitative 
study (GP and PWAUD).
X X
AUD, alcohol used isorder; CD, controlled drinking; GP, general practitioner; PWAUD, people with alcohol used isorder. 
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Iramuteq descending hierarchical classification 
includes five stages:
1. The full corpus is divided into text segments composed 
of 40 words (by default).
2. Lemmatisation: grouping of the inflected forms of a 
word so they can be analysed as a single item (verbs in 
the infinitive, nouns in the singular and adjectives in 
the masculine singular) (Unlike English, the French 
language has masculine and feminine endings for ad-
jectives).
3. Definition of a contingency table of ‘analysable’ re-
duced forms and text segments.
4. Top-down hierarchical classification analysis: per-
formed to obtain stable classes and significant associat-
ed words (tested by χ2).
5. Production of class description to enable interpretation.
Quantitative substudy
Recruitment and data collection
Recruitment started in September 2017 and is ongoing (as 
of June 2018). PWAUD are recruited in several different 
medical services such as CSAPA, clinics, hospitals, addic-
tion care services and ELSA (translated from French as 
‘Team for Linkage to Addiction Care’, ELSA is an organ-
isation of trained addiction care professionals, created 
in 2000 to increase screening and care for patients with 
AUD in hospitals. Patients recruited through ELSA are 
not yet receiving AUD care at enrolment).
Medical staff inform their patients of the study and 
provide them with the consent form. They collect the 
phone number of patients who agree to participate and 
provide related information to the investigators.
Participants are then contacted for a phone-based 
interview. Computer-assisted interviews are conducted 
by trained investigators and answers are collected using 
Sphinx software (V.IQ 2).
Interviews follow a questionnaire based on the frame-
work detailed in table 3. This questionnaire was built by 
exploring the literature on similar topics.
statistical considerations
Collected variables considered to be potentially asso-
ciated with access to care include sociodemographic 
factors, characteristics of family members (with AUD or 
not), drinking patterns, perceived stigma and perception 
about treatment for AUD (table 3).
In order to calculate the sample size, we want to 
over-represent those who have received care for AUD by a 
factor of 2 in order to compare possible ‘care subgroups’. 
A sample size of 110 versus 55 will allow us to highlight a 
strength of association with an OR 2.77 between potential 
correlates and receiving care for AUD (alpha=5% and a 
Power=80%).
Data will be analysed with STATA (Stata Statistical Soft-
ware: Release 14. College Station, Texas, USA: StataCorp 
LP). In order to control for possible recruitment biases, 
the sociodemographic characteristics of PWAUD will 
be compared between individuals recruited in the ASIA 
study and individuals in the French general popula-
tion identified with AUD in the 2016 Health Barometer 
Table 2 Semistructured PWAUD interview guide
Qualitative substudy for PWAUD
  Standard data 
collected
Audit score 
Enrolment site 
Year of birth 
Gender 
Personal situation (eg, living in a couple, having children, etc)
Professional situation (eg, employment status) 
Substance use (Yes/No, and if applicable, consumption frequency) 
Semistructured PWAUD interview guide
  Opening question You are experiencing difficulties with your alcohol consumption. I imagine it is difficult to deal with that. 
Could you tell me about your experience with alcohol since you started drinking, including, if applicable, 
your experience with health professionals for this specific problem?
  If the interviewee 
does not mention 
these topics 
spontaneously, 
the interviewer 
must do so.
 ► How long have you been drinking, how did it start?
 ► How did you realise that you had a drinking problem?
 ► Who have you talked to about your drinking problem?
 ► Have you talked about it with your family physician or another physician?
 ► What do you think prevents you from reducing or stopping your alcohol consumption?
 ► What are your goals: to stop drinking altogether? To drink less?
 ► What steps have you taken to try to change your consumption? (treatment, consultation with 
specialists, alternative medicines, etc)
 ► Have you ever taken medication to stop drinking? Which medication(s) precisely?
 ► Have you looked for information concerning treatments to stop or reduce alcohol consumption?
 ► Have you heard of baclofen? Of nalmefene?
 ► Do you visit medical websites and/or online forums? Does this help you? How?
PWAUD, people with alcohol used isorder. 
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Survey, which was conducted by the Health Prevention 
and Education National Institute (INPES). The results 
obtained will be used to decide if a weighting procedure is 
needed to make our data more representative of PWAUD 
living in France.
The main correlates of access to care for PWAUD, 
including potential barriers and levers, will be identi-
fied using univariate and multivariable logistic regres-
sion models, the outcome being ‘Having access to care 
for AUD in the three previous years medical care for 
AUD (yes/no)’. In order to control for heterogeneity 
depending on the type of care accessed by PWAUD, the 
outcome will also be expressed as a categorical ordinal 
variable and multinomial logistic regression will be used. 
Possible missing data in the outcomes can be managed 
using selection models (such as the Heckman model).25
Sensitivity analyses will be performed on specific 
subgroups (eg, those never treated vs those receiving 
pharmacological treatment for AUD) to verify results’ 
robustness.
GP population
Inclusion criteria
For both substudies (ie, quantitative and qualitative), the 
following criteria are used: working as a GP and following 
at least three PWAUD in the 3 years prior to the interview 
(even if they did not consult for AUD).
Qualitative study
Recruitment and data collection
From December 2016 to August 2017, 15 GP were 
recruited from a GP network. Recruitment took place 
using a ‘snowball method’ as follows: a member of the 
study’s research team first provided the study investigator 
with the contact information for two GP, who were then 
contacted by email. Both agreed to participate. These first 
participants were then asked for two other colleagues’ 
emails, so that they, too, could be invited, and so on. 
Information about the study and the consent form to be 
completed were sent to all GP by email.
Interviews took place in GP offices or were performed 
over the telephone and were recorded in both cases. The 
interviews were semistructured and conducted according 
to the guide described in table 4.
data analysis
Data analysis has been completed. For the GP interview 
corpus (10 hours), a manual sequenced thematic anal-
ysis26 was performed. To ensure the results’ reliability, 
four transcribed interviews were randomly selected, 
read repeatedly, analysed, coded and then categorised 
separately by the main investigator and her supervisor. 
They then discussed their respective findings together 
to identify discourse themes. The main investigator 
then conducted the initial coding of all 15 transcribed 
Table 3 PWAUD questionnaire
Section 
number Main theme Specific themes
1 General information Age, gender, family situation, educational status, income, employment status, quality 
of housing, receiving ordinary healthcare, access to transportation, internet access.
2 Alcohol consumption Craving level, health issues related to alcohol consumption, withdrawal symptoms, 
alcohol consumption perceptions
3 Substances use other than 
alcohol
Tobacco, opioids, benzodiazepines, cocaine, synthetic drugs
4 Experiences and perceptions 
related to alcohol consumption
Feelings, discrimination, drinking environment (place, peers)
5 AUD aims concerning personal 
alcohol consumption
(eg, abstinence, reduction, etc)
6 Care received Having a regular GP, quality of relationship with regular GP, receiving/having received 
care (in the 3 years prior to enrolment), having already sought AUD care through 
regular GP or in general, and, if applicable, reasons for not having sought AUD care.
7 Methods used to stop or 
reduce alcohol consumption
Medical methods, alternative therapies, association support. For each method, 
participants are asked if it was/is helpful and if it is ongoing.
8/9 Pharmacological treatments Pharmacological treatments: Question 8 is designed for PWAUD who have already 
had at least one experience with pharmacological treatment, while question 9 is 
for people who have never taken any pharmacological treatment. For each of the 
five prescribed pharmacological treatments for maintaining abstinence or reducing 
alcohol consumption, participants are asked (1) if they have heard of it (if applicable 
where/from whom), (2) if they have taken the treatment (if applicable, who prescribed 
it to them), (3) reasons for deciding to take or not to take this treatment, (4) the 
treatment’s efficacy and (5) (if appropriate) their personal opinion about the causes 
for failure using this treatment.
AUD, alcohol used isorder; GP, general practitioner; PWAUD, people with alcohol use d isorder. 
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interviews according to the previously identified themes. 
After preliminary analysis, the coding framework was 
discussed and approved by all the study group members. 
The main investigator then conducted the final coding.
Quantitative substudy
Recruitment and data collection
Recruitment started in May 2017 and is ongoing (as of 
May 2018). GP are recruited randomly from the French 
professional phonebook. Inclusion criteria are the same 
as for the qualitative study. After receiving informa-
tion on the study and providing consent, participants 
are contacted to perform the survey. Just as for the 
PWAUD quantitative study, computer-assisted interviews 
are conducted by trained investigators and answers are 
collected using Sphinx software (V.IQ2). Interviews follow 
a questionnaire based on the guide detailed in table 5. 
Table 4 Semistructured GP interview guide
Qualitative substudy among GP
  Standard data collected Year of birth 
Gender 
Beginning date of professional practice 
Workplace category (urban, rural or semirural) 
Semistructured GP interview guide
  Opening question Can you tell me about your experience with patients with alcohol use disorder, especially how you 
handle them?
  If the interviewee does 
not mention these topics 
spontaneously, the 
interviewer must do so:
 ► Are you currently following patients with alcohol use disorder?
 ► How do you screen for alcohol use disorder? Do you use a specific scale or test?
 ► Do you treat patients by yourself for substance abuse or do you refer them to a colleague or a 
specialised centre?
 ► Do you prescribe pharmacological treatments to help with the suppression/reduction of alcohol 
consumption? Which ones?
 ► What motivates this choice of treatment?
 ► Do you think it is possible to stop drinking without treatment?
 ► Do you think that abstinence is the only possible answer for people who have a drinking 
problem?
 ► Do you consider that reducing consumption is an acceptable therapeutic objective (with 
respect to abstinence)?
 ► What do you think about baclofen and nalmefene?
GP, general practitioner. 
Table 5 GP questionnaire
GP questionnaire
Section 
number Main theme Specific themes
1 General information about 
GP and their practice
Gender, age, practice duration (years), number of regular patients, consultation duration, 
addictology training, participation in an addictology network, opioid maintenance 
treatment prescription, interest in addictology, tobacco cessation management.
2 Alcohol consumption 
screening: alcohol 
cessation/reduction 
management
Performs screening (yes or no, alone or with another healthcare professional and, if 
applicable, which category of professional), reason for not managing patient alcohol 
cessation, number of patients with AUD, prescribes blood analysis to screen for AUD 
(yes or no), AUD spontaneous assessment (if applicable, with which tool/scale), uses a 
brief intervention (yes or no), knowledge of specialised alcoholism network structures 
(for nine different structures, GP are asked if they know the structure and if they 
collaborate with it).
3 AUD management (if 
applicable)
AUD management motivations, treatment/orientation/advice provided, pharmacological 
treatment prescription (yes or no and, if applicable, the reason for not prescribing 
pharmacological treatment to stop or reduce alcohol consumption), prescription of one 
of the five pharmacological treatments indicated to stop or reduce alcohol consumption 
(for each treatment: treatment prescription intention, prescription motivation, treatment 
risk–benefit opinion, opinion about causes for treatment failure, opinion about causes 
for poor adherence and treatment cessation).
4 Opinion question ‘Do you think that abstinence is the only acceptable therapeutic goal for PWAUD? (Yes, 
no, I don’t know)’, and ‘Do you think that CD is a realistic therapeutic goal for PWAUD? 
(Yes, no, I don’t know)’.
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The questionnaire was built by exploring the literature 
on similar topics.
In order to calculate the sample size, we assumed a 50% 
prevalence of GP not providing AUD. In order to be able 
to identify an OR equal to 3.5 when comparing the risk of 
not providing care when being exposed or non-exposed 
to a potential correlate, with 80% power and a 0.05 alpha 
risk, we calculated that we need to recruit at least 46 GP 
who provide AUD care and 46 who do not. We rounded 
this total to 50 and 50 (100 GP in total).
statistical considerations
Outcomes and potential correlates (See table 5)
The four following outcomes will be explored:
1. Systematic AUD screening (table 5, Section 2)
2. AUD management (table 5, Section 3)
3. Acceptance of CD as a therapeutic goal (table 5, Sec-
tion 4)
4. Prescription of pharmacological treatment (table 5, 
Section 3)
Potential variables that will be considered for analysis 
include demographic and professional characteristics/
practices, number of patients with AUD and perceived 
barriers to engaging patients in care for AUD (lack of 
training, patient’s denial of AUD, lack of time, complexity 
of AUD patients’ profile (ie, several concurrent psycho-
logical and physiological comorbidities).
Percentages, median and IQR will be used to describe 
the characteristics of the study group. In order to iden-
tify correlates of the three outcomes, we will use logistic 
regression models.
Potential explanatory variables of all four outcomes are 
described in the questionnaire outlined in table 5. Logistic 
regression models will be used to compute both crude 
and adjusted OR and their 95% CI in order to obtain an 
estimate of the strength of the association between each 
explanatory variable and each outcome.
Variables with a liberal p value <0.20 will be considered 
eligible for the multivariable models which will be built 
using a backward procedure based on the likelihood ratio 
test (p<0.05). Perceived barriers to AUD engagement 
in care will be eligible for the final multivariable model 
independently of the p value obtained in the bivariable 
analysis, due to the high risk of confounding.
All the analysis will be performed using STATA SE/12.1.
Identifying GP who are likely to prescribe treatment 
for AUD and those who are not may help target future 
interventions to improve screening and treatment for 
PWAUD.
dIsCussIon
The originality of the present protocol lies in the use of the 
combination of a mixed-method and a ‘double-perspec-
tive’ design. Various studies exploring both healthcare 
providers’ and patients’ points of view have highlighted 
differences in expectations, priorities and perceptions of 
each of the two populations, and identified the need to 
develop patient-centred care strategies.27–29 We believe 
that our study will confirm these findings and bring to 
light some new concerns in the field of AUD care. The use 
of a qualitative and quantitative mixed-method approach 
is, in our opinion, very pertinent, as alcohol consumption 
is highly integrated into various sociocultural patterns 
and differs greatly from one context to another.30 Qual-
itative study approaches are especially useful to increase 
sociocultural understanding.31 The replication of this 
study would be of great value for several reasons: the 
use of the mixed-method approach permits an in-depth 
exploration of the different aspects of access to care in a 
specific context, and the double-perspective design leads 
to a greater understanding of the differences between the 
two populations’ views and perceptions.
The use of two different qualitative analysis methods 
may seem questionable but can be justified by the differ-
ence between the volume of data for GP and for PWAUD. 
More specifically, as the PWAUD interview corpus was very 
large (35 hours), the use of a software-assisted thematic 
and lexical content analysis seemed an appropriate 
choice. As the GP qualitative data were less substantial, 
manual thematic analysis seemed more appropriate. Data 
obtained using these two methods can easily be compared 
and researchers aiming to reproduce this study have the 
choice of using one or both of these same methods to 
analyse qualitative data.
We believe results from ASIA will be of great use in 
the development of future recommendations and the 
updating of care guidelines for GP, an important element 
being clear information about AUD care networks. The 
ASIA study’s results will be disseminated via peer-reviewed 
publications, conference presentations and in general 
public media.
Ethics and dissemination
The confidentiality and anonymity of participant data will 
be guaranteed for both GP and PWAUD in every step of 
the study; no information will be kept which could result 
in participants being identified. Audio-recorded inter-
views will be transcribed and deleted within 3 months 
after recording. Only the main investigator will have 
access to the recordings. For both populations, participa-
tion in the quantitative and/or the qualitative substudy 
will only occur if written consent is given after the indi-
vidual has been provided with a document explaining 
ASIA modalities and objectives.
This study was approved by the CNIL (French National 
Commission on Informatics and Liberties) (approval 
reference number: C16-10 , d ate of approval: 17 July 
2017), the  CCTIRS (Advisory Committee on Information 
Processing in Material Research in the Field of Health) 
and the CEEI (Evaluation and Ethics Committee) 
(approval reference number: 16 – 312, d ate of approval: 
8 July 2016) of INSERM (French National Institute of 
Health and Medical Research). 
Results from ASIA will be disseminated at several 
levels: We plan to publish four articles in peer-reviewed 
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international scientific journals covering the fields of 
public health, general practice and substance use disor-
ders. We also plan to present our significant results in 
national and international congresses and events for 
professionals working within the field of AUD and health 
prevention.
The ASIA project will result in a PhD thesis, which will 
be defended in 2019.
A short report presenting ASIA main results will be 
distributed in PWAUD recruitment sites for staff and 
patients.
By the end of 2019, a presentation of ASIA results 
will be performed at the MILDECA (French inter-min-
isterial mission for the fight against drugs and addictive 
behaviours), the French government organisation which 
coordinates actions related to campaign against addictive 
behaviours. It will enable the design of recommenda-
tions to raise the awareness of GP about the necessity of 
improving screening and care for alcohol use disorder in 
their routine practice.
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